Will Congress extend the popular QTDP program?; Leo Pharma to collaborate with Scripps

@FierceBiotech: Nabi shares in meltdown after NicVAX flunks Ph3. Story | Follow @FierceBiotech

@JohnCFierce: Look for Alkermes to talk a lot about sustained growth with EDT acquisition. Here's the PR: Release | Follow @JohnCFierce

> Few government programs has been as popular among biotech companies as the Qualifying Therapeutic Discovery Project, which delivered a billion dollars in R&D support to small developers. Now some members of Congress are out to revive the QTDP and extend the bonus out to 2017. This time around, though, lawmakers are more focused on budget cuts, making this effort an uphill fight at best. Report

> Leo Pharma says that it will collaborate with the Scripps Research Institute on new skin disease treatments. Release

> Fast on the heels of raising $25.8 million in new venture funds, New York-based Coronado Biosciences has filed to go become a public reporting company through a Form 10. Coronado is working on new immunotherapies for AML and autoimmune diseases like MS. Release

> San Diego-based Zogenix received a $30 million revenue investment advance from Cowen Royalty today. Release

> Nektar Therapeutics reports that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion on its application for orphan medicinal product status for the company's lead oncology candidate, NKTR-102, for ovarian cancer. Release

Pharma News

@FiercePharma: Roche to post 'massive' margin boost, paper says. Item | Follow @FiercePharma

> Hong Kong forces second GSK recall. Story

> Novartis Q2 shines on new meds, cost cuts. Article

Biotech Research News

> New weapon found in war against triple-negative breast cancer. More

> Group launches program to develop drugs for pediatric HIV. Article

> Addiction recognized as medical condition, not lack of willpower. News

> Lack of funding shuts down Maine biotech research. Piece

> Nanosensors on cells show how they communicate in real time. Report

> Mice receive artificial human liver for drug testing. Item

Manufacturing News

> Vietnamese officials crack down on substandard drugs. Article

> One man's foreign-source warning is another's generics bash. News

> MIT works toward bioprocess predictability, drug quality. Report

> Intel eyes pharma road to 'next billion users.' Story

> WHO touts flu, pandemic vax readiness. Item

> Rx-360 shores up raw material security. Story

And Finally...What was supposed to have been a major biomedical research center in Maine when it was unveiled in 2005 is shutting down the centerpiece of its program due to lack of funding, according to the Bangor Daily News. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.